Immunodiagnostic Systems, the Newcastle based niche Diagnostics Company, reported in the AGM update that sales for the five months to August 2011 were £22.6 million (2010: £18.4 million).
At August 2011, the IDS-iSYS estate totalled 299 istruments (March 2011: 241), with a further 15 instruments anticipated to be placed or sold in September. Average revenue per instrument is £88,000 vs. £72,000 in August 2010. The traditional H2 weighting is anticipated to be more pronounced than previously due to both a seasonally quieter July and August and also higher anticipated reagent/instrument sales pull-through. The company remain active in examining the potential for licensing-out the automated IDS-iSYS platform into disease areas which it does not serve.
The IDH share price has increased by 28% over the last year.
Immunodiagnostic Systems Holdings Plc is currently graded B by LCF Research. To learn more, follow the link.
